Zhi Tong Cai Jing·2026-03-04 08:41Core Viewpoint - Shandong Xinhua Pharmaceutical's subsidiary has received approval for a new diabetes medication, which is expected to enhance the company's competitive position in the market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has been granted a drug registration certificate for the Saxagliptin Metformin Extended-Release Tablets (I) and (III) by the National Medical Products Administration [1] - The medication is intended for adult patients with type 2 diabetes to improve blood sugar control and is not suitable for type 1 diabetes or diabetic ketoacidosis patients [1] Group 2: Market Potential - The Saxagliptin Metformin Extended-Release Tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - The projected sales revenue for Saxagliptin Metformin Extended-Release Tablets in Chinese public medical institutions is approximately RMB 419 million in 2024 [1] Group 3: Strategic Implications - The approval of this medication will enrich the company's range of hypoglycemic agents, thereby enhancing its overall competitiveness in the pharmaceutical market [1]